EMC Capital Management Reduces Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

EMC Capital Management cut its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 76.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,500 shares of the company's stock after selling 8,273 shares during the quarter. EMC Capital Management's holdings in Hims & Hers Health were worth $60,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares during the period. GAMMA Investing LLC increased its position in shares of Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company's stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company's stock worth $110,000 after purchasing an additional 2,442 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Trading Up 9.9 %

Shares of NYSE HIMS traded up $3.37 during midday trading on Friday, reaching $37.33. 19,688,822 shares of the company were exchanged, compared to its average volume of 8,894,710. The stock has a market cap of $8.16 billion, a P/E ratio of 84.85 and a beta of 1.31. Hims & Hers Health, Inc. has a 1 year low of $8.51 and a 1 year high of $37.96. The stock has a fifty day simple moving average of $29.20 and a 200 day simple moving average of $22.57.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the firm earned ($0.04) EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the firm's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares of the company's stock, valued at $1,399,273.20. This trade represents a 73.81 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patrick Harrison Carroll sold 15,000 shares of the company's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.07, for a total value of $331,050.00. Following the transaction, the insider now directly owns 196,941 shares in the company, valued at $4,346,487.87. This represents a 7.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,256,067 shares of company stock valued at $34,459,485. 17.71% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on HIMS. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target on the stock. TD Cowen reissued a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Citigroup cut Hims & Hers Health from a "neutral" rating to a "sell" rating and boosted their target price for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Monday, January 6th. Finally, Piper Sandler boosted their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a research report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.